MAPT and Alzheimer disease: Due to the well-known disadvantages of current standard measures of AD biomarkers, namely, their expensive cost and invasiveness, a convenient, inexpensive, and easily accessible test that predicts amyloid and tau status would therefore reduce the burden and cost of clinical AD trials.